This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Efficacy and Associated Cost Savings

Carol Brignoli Gable, PhD, MA; Susan Sedory Holzer, MA; Luella Engelhart, MA; Rhonda B. Friedman, ScD; Frank Smeltz; Don Schroeder, PhD; Kristina Baum, MBA

JAMA. 1990;264(22):2910-2915.

Abstract
We evaluated the efficacy and cost savings of the pneumococcal pneumonia vaccine in a retrospective cohort study of 762 vaccinated and 1161 randomly selected unvaccinated age-sex matched persons in Blue Cross/Blue Shield of Minnesota using medical and pharmaceutical claims. The pneumonia incidence and the ratio of incidence in the postvaccination to prevaccination periods (rate ratio) were examined in the vaccine group by sex and risk factors. Vaccination significantly reduced pneumonia incidence, with overall efficacy of 69% and higher efficacy in women (86%) than in men (33%). We assigned persons to risk categories based on disease conditions as recorded in the claims by the ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical Modification) diagnostic codes. In the risk categories, efficacy varied from 50% to 75% and was confounded by sex. Immunocompromised and immunocompetent women had high efficacy (83% to 88%), while immunocompetent and immunocompromised men had lower efficacy (33%). Persons with a precondition of pneumonia exhibited similar vaccine efficacy to the overall cohort relative to the comparison group. Projected costs of pneumonia cases are 3.6 times the observed costs of vaccination and postvaccination pneumonia costs. We conclude that the pneumococcal pneumonia vaccine is efficacious in persons having had pneumonia, persons "at risk" of developing pneumonia, or persons over 50 years of age, and it corresponds to overall savings of $141 per person.

(JAMA. 1990;264:2910-2915)

Author Affiliations
From the Medical Technologies Assessment Division, SysteMetrics/McGraw-Hill, Washington, DC.

Footnotes
Reprint requests to SysteMetrics/McGraw-Hill, 4401 Connecticut Ave NW, Suite 400, Washington, DC 20008 (Dr Gable).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Preventive Health Care in the Elderly Population: A Guide for Practicing Physicians
Takahashi et al.
Mayo Clin Proc. 2004;79:416-427.
ABSTRACT  

Cost-Effectiveness of the Pneumococcal Vaccine in Healthy Younger Adults
Pepper and Owens
Med Decis Making 2002;22:S45-S57.
ABSTRACT  

Cost-Benefit Analysis of a New HEDIS Performance Measure for Pneumococcal Vaccination
Ahmed et al.
Med Decis Making 2002;22:S58-S66.
ABSTRACT  

In Nonrandomized Studies, Can We Use A Person's Preimmunization Experience to Help Gauge the Safety and Efficacy of Immunization?
Weiss and Davis
Am J Epidemiol 2002;156:395-396.
FULL TEXT  

The Health and Economic Benefits Associated With Pneumococcal Vaccination of Elderly Persons With Chronic Lung Disease
Nichol et al.
Arch Intern Med 1999;159:2437-2442.
ABSTRACT | FULL TEXT  

Prognosis After Community-Acquired Pneumonia in the Elderly: A Population-Based 12-Year Follow-up Study
Koivula et al.
Arch Intern Med 1999;159:1550-1555.
ABSTRACT | FULL TEXT  

A Hospital-Based Pharmacy Intervention Program for Pneumococcal Vaccination
Vondracek et al.
Arch Intern Med 1998;158:1543-1547.
ABSTRACT | FULL TEXT  

Incidence of Community-Acquired Pneumonia Requiring Hospitalization: Results of a Population-Based Active Surveillance Study in Ohio
Marston et al.
Arch Intern Med 1997;157:1709-1718.
ABSTRACT  

Pneumococcal vaccine campaign based in general practice
McDonald et al.
BMJ 1997;314:1094-1094.
ABSTRACT | FULL TEXT  

Oregon's Medicaid Ranking and Cost- Effectiveness: Is There Any Relationship?
Tengs et al.
Med Decis Making 1996;16:99-107.
ABSTRACT  

The Prevalence of Drug-Resistant Streptococcus pneumoniae In Atlanta
Hofmann et al.
NEJM 1995;333:481-486.
ABSTRACT | FULL TEXT  

Counterpoint to 'Pneumococcal Vaccine After 1 5 Years of Use'
Ruben
Arch Intern Med 1995;155:771-772.
ABSTRACT  

Counterpoint to 'Pneumococcal Vaccine After 1 5 Years of Use'-Reply
Hirschmann and Lipsky
Arch Intern Med 1995;155:772-773.
ABSTRACT  

Prevention of Respiratory Infections in Adults: Influenza and Pneumococcal Vaccines
Fiebach and Beckett
Arch Intern Med 1994;154:2545-2557.
ABSTRACT  

The Pneumococcal Vaccine After 15 Years of Use
Hirschmann and Lipsky
Arch Intern Med 1994;154:373-380.
ABSTRACT